Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses a multi-center analysis of outcomes for patients with relapsed/refractory (R/R) multiple myeloma (MM) treated with the bispecific antibody teclistamab in real-world practice. Although a large proportion of the patients included in the analysis would not have been eligible for the MajesTEC-1 trial (NCT04557098), safety signals and response rates were comparable to those observed in the trial setting. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть